,0
symbol,STSA
price,4.195
beta,0.0
volAvg,2406289
mktCap,73065576
lastDiv,0.0
range,3.5-36.105
changes,0.155
companyName,Satsuma Pharmaceuticals Inc
currency,USD
cik,0001692830
isin,US80405P1075
cusip,80405P107
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://www.satsumarx.com/
description,"Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 16 full-time employees. The firm is focused on developing a therapeutic product for the treatment of migraine. The Companyâ€™s product candidate STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be self-administered with a proprietary pre-filled, single-use, nasal delivery device."
ceo,Mr. John Kollins
sector,Healthcare
country,US
fullTimeEmployees,20
phone,14155050809
address,400 Oyster Point Blvd Ste 221
city,South San Francisco
state,CALIFORNIA
zip,94080
dcfDiff,
dcf,7.74002
image,https://financialmodelingprep.com/image-stock/STSA.png
ipoDate,2019-09-13
defaultImage,False
